{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:07Z","timestamp":1787721667516,"version":"build-2784847793"},"reference-count":44,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2716508","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:32:55Z","timestamp":1787718775000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in USA and Puerto Rico: Results from a Phase III, randomized, active-controlled study"],"prefix":"10.1080","volume":"22","author":[{"given":"Abraham","family":"Moskow","sequence":"first","affiliation":[{"name":"Rainbow Research Inc.","place":["Barnwell, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-1584","authenticated-orcid":false,"given":"Sandeep","family":"Gupta","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Swiftwater, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep Singh","family":"Dhingra","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Swiftwater, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Montevideo, Uruguay"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gan","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Swiftwater, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"B\u2019Chir","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Marcy L\u2019 Etoile, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Syrkina","sequence":"additional","affiliation":[{"name":"Patient Safety & Pharmacovigilance","place":["Sanofi, Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Hagenbach","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Marcy L\u2019 Etoile, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lyabis","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Marcy L\u2019 Etoile, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rehm","sequence":"additional","affiliation":[{"name":"Global Clinical Development","place":["Sanofi, Swiftwater, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"About Meningococcal Disease. CDC. US Centers for Disease Control and Prevention. 2026 [accessed 2026 Mar 5]. https:\/\/www.cdc.gov\/meningococcal\/about\/index.html."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.062"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13342-2"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.079"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/649209"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2035"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.04.012"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1258308"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010409"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix993"},{"key":"e_1_3_5_12_1","unstructured":"Enhanced Meningococcal Disease Surveillance Report (EMDS). CDC. US Centers for disease control and prevention. 2023. [accessed 2026 Mar 5]. https:\/\/www.cdc.gov\/meningococcal\/media\/pdfs\/2025\/04\/NCIRD-EMDS-Report-2023_508.pdf."},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"e_1_3_5_14_1","unstructured":"MenQuadfi: prescribing information. US FDA. 2025 [accessed 2026 Mar 5]. https:\/\/www.fda.gov\/media\/137306\/download?attachment."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.01.050"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2588874"},{"key":"e_1_3_5_17_1","first-page":"1306","volume-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study","author":"Vesikari T","year":"2020","unstructured":"Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study. Hum Vaccin Immunother. 2020;16:1306\u20131312."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000261"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000698"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002832"},{"key":"e_1_3_5_21_1","first-page":"1","volume-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a Phase III, open-label, multi-center study","author":"Piazza FM","year":"2022","unstructured":"Piazza FM, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, Forsten A, Seppa I, Ding J, Neveu D, Jordanov E. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a Phase III, open-label, multi-center study. Hum Vaccin Immunother. 2022;18:1\u201310."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.017"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.013"},{"key":"e_1_3_5_24_1","first-page":"1292","volume-title":"Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study","author":"\u00c1\u00f1ez G","year":"2020","unstructured":"\u00c1\u00f1ez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, Pan J, Jordanov E, MS Dhingra. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020;16:1292\u20131298."},{"key":"e_1_3_5_25_1","first-page":"1299","volume-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study","author":"Kirstein J","year":"2020","unstructured":"Kirstein J, Pina M, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. Hum Vaccin Immunother. 2020;16:1299\u20131305."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.04.067"},{"key":"e_1_3_5_27_1","unstructured":"Defeating meningitis by 2030: a global road map. World Health Organization (WHO); 2021 https:\/\/www.who.int\/publications\/i\/item\/9789240026407. [accessed 5 March 2026]."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.829"},{"key":"e_1_3_5_29_1","unstructured":"Recommended immunization schedule for children and adolescents aged 18 years or younger UNITED STATES. CDC. US Centers for Disease Control and Prevention; 2018. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/downloads\/past\/2018-child.pdf. [accessed 5 March 2026]."},{"key":"e_1_3_5_30_1","unstructured":"Recommended child and adolescent immunization schedule for ages 18 years or younger. CDC. US Centers for disease control and prevention. 2025. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/downloads\/past\/2025-child.pdf. Accessed 5 March 2026."},{"key":"e_1_3_5_31_1","unstructured":"Summary of WHO position papers - recommended routine immunizations for children. World Health Organization (WHO); 2025. https:\/\/www.who.int\/publications\/m\/item\/table-2-summary-of-who-position-papers-recommended-routine-immunizations-for-children. [accessed 5 March 2026]."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000251"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.09.008"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.859"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2188852"},{"key":"e_1_3_5_37_1","first-page":"12","article-title":"SMS-Based active surveillance of adverse events following immunization in children: the VigiVax study","author":"Gonella LA","year":"2024","unstructured":"Gonella LA, Moretti F, Capuano A, De Sarro C, Ferrara L, Geninatti E, Guarnieri G, Hysolakoj X, Lalli M, Leoni O, AMP Mangano. SMS-Based active surveillance of adverse events following immunization in children: the VigiVax study. Vaccines (Basel). 2024;12(9):1076.","journal-title":"Vaccines (Basel)"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-0665"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004407.pub5"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.02.041"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.072"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.036"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003277"},{"key":"e_1_3_5_44_1","unstructured":"Study results: immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in infants and toddlers when administered concomitantly with routine pediatric vaccines in the United Kingdom (NCT03632720). Clinicaltrials.gov; 2023 [accessed 2026 Mar 5]. https:\/\/clinicaltrials.gov\/study\/NCT03632720?tab=researcher."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01190-7"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2716508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2026.2716508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2716508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:33:09Z","timestamp":1787718789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2716508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2716508"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2716508","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2716508"}}